Abstract
Among the multiple pharmacologic and non-pharmacologic therapies, beta-blockers seem to be the mainstay of heart failure management. Although the first large studies failed to demonstrate a significant improvement in mortality, the results from subsequent studies revealed significant risk reductions in mortality with metoprolol, carvedilol and bisoprolol. Decision of the appropriate therapeutic agent depends on the existence of some specific conditions complicating dilated cardiomyopathy. This article reviews the impact of beta-blocker therapy in patients with dilated cardiomyopathy of ischemic or non-ischemic etiology.
Keywords: Dilated Cardiomyopathy, Beta-blocker Therapy, beta-blockers, heart failure, metoprolol, carvedilol, bisoprolol, Congestive heart failure, angiotensin-converting enzyme, angiotensin receptor blockers, aldos-terone antagonists, left ventricular, arrhythmias, Catecholamines, cardiomyocytes, renin-angiotensin, apoptosis, myocardial fibers is reduced, the sarcoplasmic reticulum, placebo-controlled, receptors, nebivolol, hemodynamics, bradycardia, Atrial fibrillation, sinus rhythm, Peripheral vascular disease, hypoglycemia, glycosylated hemoglobin, chronic obstructive pulmonary disease, bronchospasm
Current Pharmaceutical Design
Title: Beta-Blockers in the Treatment of Dilated Cardiomyopathy: Which is the Best?
Volume: 16 Issue: 26
Author(s): Kursat Tigen and Cihan Cevik
Affiliation:
Keywords: Dilated Cardiomyopathy, Beta-blocker Therapy, beta-blockers, heart failure, metoprolol, carvedilol, bisoprolol, Congestive heart failure, angiotensin-converting enzyme, angiotensin receptor blockers, aldos-terone antagonists, left ventricular, arrhythmias, Catecholamines, cardiomyocytes, renin-angiotensin, apoptosis, myocardial fibers is reduced, the sarcoplasmic reticulum, placebo-controlled, receptors, nebivolol, hemodynamics, bradycardia, Atrial fibrillation, sinus rhythm, Peripheral vascular disease, hypoglycemia, glycosylated hemoglobin, chronic obstructive pulmonary disease, bronchospasm
Abstract: Among the multiple pharmacologic and non-pharmacologic therapies, beta-blockers seem to be the mainstay of heart failure management. Although the first large studies failed to demonstrate a significant improvement in mortality, the results from subsequent studies revealed significant risk reductions in mortality with metoprolol, carvedilol and bisoprolol. Decision of the appropriate therapeutic agent depends on the existence of some specific conditions complicating dilated cardiomyopathy. This article reviews the impact of beta-blocker therapy in patients with dilated cardiomyopathy of ischemic or non-ischemic etiology.
Export Options
About this article
Cite this article as:
Tigen Kursat and Cevik Cihan, Beta-Blockers in the Treatment of Dilated Cardiomyopathy: Which is the Best?, Current Pharmaceutical Design 2010; 16 (26) . https://dx.doi.org/10.2174/138161210793176473
DOI https://dx.doi.org/10.2174/138161210793176473 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Serum Collagen Markers and Heart Failure
Cardiovascular & Hematological Disorders-Drug Targets Melatonin Alleviates Pyroptosis of Retinal Neurons Following Acute Intraocular Hypertension
CNS & Neurological Disorders - Drug Targets Emerging Molecular Targets for Treatment of Erectile Dysfunction: Vascular and Regenerative Therapies on the Horizon
Current Drug Targets Metabolic Features of Alcoholic Liver Disease
Reviews on Recent Clinical Trials Cardiovascular Disease in Antiphospholipid Syndrome
Current Vascular Pharmacology Management of Chemotherapy Induced Cardiomyopathy
Current Cardiology Reviews Transposable Elements in Cancer and Other Human Diseases
Current Cancer Drug Targets Antithrombotic Treatment after Atrial Fibrillation Ablation
Current Pharmaceutical Design subject Index To Volume 1
Current Molecular Medicine Clinical Implications of Recent Insights into the Structural Biology of Beta2 Adrenoceptors
Current Drug Targets L-carnitine: Searching for New Therapeutic Strategy for Sepsis Management
Current Medicinal Chemistry Peroxisome Proliferator-Activated Receptor (PPAR)β /δ: A New Potential Therapeutic Target for the Treatment of Metabolic Syndrome
Current Molecular Pharmacology Syncope: Review of Monitoring Modalities
Current Cardiology Reviews Pro- and Anti-Arrhythmic Effects of Anti-Inflammatory Drugs
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Stage A: Can Heart Failure Be Prevented?
Current Cardiology Reviews Differential Contribution of Clinical Amounts of Acetaldehyde to Skeletal and Cardiac Muscle Dysfunction in Alcoholic Myopathy
Current Pharmaceutical Design Editorial:Circulating Biomarkers in Cardiovascular Diseases – A Field of Theoretical Research or Realistic Clinical Application?
Current Pharmaceutical Biotechnology Determination of Stimulants and Diuretics in Dietary Supplements for Weight Loss and Physical Fitness by Ion-pair Chromatography and Pulsed Amperometric Detection (PAD)
Current Analytical Chemistry Cardiomyopathy of Pregnancy
Current Women`s Health Reviews Nanomedicine for Gene Delivery for the Treatment of Cardiovascular Diseases
Current Gene Therapy